Core Insights - BrainStorm Cell Therapeutics Inc. reported its financial results for the full year 2025 and highlighted advancements in its clinical programs, particularly for NurOwn, a treatment for ALS [1][2]. Financial Performance - For the year ended December 31, 2025, the company reported a net loss of approximately $10.3 million, an improvement from a net loss of about $11.6 million in 2024 [9][17]. - Research and development expenditures for 2025 were $4.2 million, down from $4.7 million in 2024 [9][17]. - General and administrative expenses decreased to approximately $5.8 million in 2025 from $7.0 million in 2024 [9][17]. - Cash and cash equivalents were approximately $0.3 million as of December 31, 2025, with an additional $2 million secured through private placements in early 2026 [9][3]. Clinical Development - The company is advancing NurOwn into a Phase 3b confirmatory study, having received FDA clearance in 2025 [2]. - The Phase 3b ENDURANCE study is expected to enroll around 200 participants and will consist of a 24-week randomized, double-blind, placebo-controlled portion followed by a 24-week open-label extension [2][4]. - The primary efficacy endpoint for the trial will be the change from baseline to Week 24 on the ALSFRS-R scale [2]. Expanded Access Program (EAP) Results - In the EAP, 50% of patients (5 out of 10) remained alive, with an estimated mean survival of approximately 84 months [4]. - All 10 EAP patients exceeded a 5-year survival rate compared to the historical rate of about 20% [4]. Strategic Financing - The company secured $2 million in strategic financing through two private placement agreements in February 2026, aimed at supporting operational objectives and the Phase 3b trial preparations [3][9]. Technology Overview - NurOwn technology utilizes autologous MSC-NTF cells derived from bone marrow to deliver neurotrophic factors, targeting neurodegenerative diseases [5][6]. - The platform has received Orphan Drug designation from both the FDA and EMA for ALS treatment [7].

Core Viewpoint - Bank OZK is set to report its first quarter 2026 earnings on April 21, 2026, after market close, with management comments released simultaneously [1] Group 1: Earnings Announcement - The earnings report for the first quarter of 2026 will be available on the Bank's investor relations website [1] - A conference call for questions will be held on April 22, 2026, at 7:30 a.m. CT (8:30 a.m. ET) [2] - Participants can access the conference call via webcast or telephone, with registration required for telephone access [2] Group 2: Company Overview - Bank OZK, established in 1903, operates 268 offices across nine states, including Arkansas, Georgia, Florida, Texas, North Carolina, Tennessee, New York, California, and Mississippi [3] - As of December 31, 2025, the Bank had total assets of $40.8 billion [3]

Core Viewpoint - T1 Energy Inc. reported Q4 2025 results with record module production but faced a significant net loss due to heavy investments in scaling operations, leading to investor disappointment despite ongoing progress on the G2_Austin solar cell project [3][4][7]. Financial Performance - T1 Energy achieved record quarterly module production of 1.13 GW, generating $358.6 million in revenue, which was below analyst expectations of $368.2 million [3][4][7]. - The company reported a GAAP net loss of $190 million, translating to an EPS of -$0.87, which was a significant improvement from -$2.59 per share in Q4 2024 [3][7]. - The loss from continuing operations was approximately $153 million, with an EPS of -$0.70 [7]. G2_Austin Solar Cell Project - The G2_Austin project is progressing well, with construction on the first 2.1 GW phase underway and on schedule for commercial production by late 2026 [4][6]. - The project is expected to create up to 1,800 jobs and significantly increase U.S. solar cell manufacturing capacity, exceeding current total U.S. silicon-based cell capacity [4]. - T1 Energy is targeting financial close for the remaining ~$350 million of funding in April 2026 and has optimized project costs through efficient capital use [5][7]. Strategic Partnerships and Growth - The company has partnered with Yates Construction for the G2_Austin project and is collaborating with technology and supply chain partners to enhance project execution [5]. - T1 Energy is in a growth phase, focusing on rapid revenue scaling from its G1_Dallas factory and major capacity expansion via G2_Austin, with expectations of improved margins and profitability in 2027 and beyond [6].

Core Insights - The S&P 500 ETF experienced a decline of over 5% in March due to the impact of the war in Iran, which caused a significant increase in oil prices [1] Group 1: Market Performance - The S&P 500 ETF (SP500, SPY) fell more than 5% during March [1] Group 2: Geopolitical Impact - The war in Iran led to soaring oil prices, contributing to the decline in stock prices [1] - Despite the downturn, there were emerging geopolitical rays of hope towards the end of the quarter [1]

Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company")  (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to i ...

Core Insights - Jushi Holdings Inc. reported a total revenue of $262.9 million for the full year 2025, reflecting a 2% increase year-over-year, driven by contributions from new store openings [1][6] - The company achieved operational improvements in 2025, enhancing cultivation performance and product availability [1][8] - Jushi refinanced its debt post year-end, extending maturities to 2029, which improved liquidity and strengthened the balance sheet [1][7] Financial Highlights - For Q4 2025, total revenue was $68.3 million, with a gross profit of $28.6 million and a gross profit margin of 41.9% [6][9] - The net loss for Q4 2025 was $15.6 million, while adjusted EBITDA was $13.9 million, resulting in an adjusted EBITDA margin of 20.4% [6][9] - For FY 2025, the gross profit was $114.0 million, with a gross profit margin of 43.4%, despite a net loss of $68.6 million [6][9] Operational Developments - Jushi expanded its retail footprint with eight new store openings, ending the year with 42 operating dispensaries across eight states [6][10] - The company introduced 280 new unique SKUs across its product portfolio, indicating continued innovation [6][10] - Jushi-branded products accounted for 58% of retail revenue, an increase of 332 basis points year-over-year [6][12] Market and Legislative Context - Virginia's adult-use cannabis legislation was passed, establishing a regulated retail market with sales expected to begin on January 1, 2027, pending the Governor's approval [1][8] - The company is positioned to benefit from the anticipated expansion of the cannabis market in Virginia due to its existing infrastructure [8][10] Balance Sheet and Liquidity - As of December 31, 2025, Jushi had approximately $26.6 million in cash and cash equivalents, with total debt of $207.8 million [14][29] - The refinancing of existing loans was completed through a $160.0 million secured term loan, enhancing financial flexibility [7][14] Shareholder Information - As of March 24, 2026, the company had 199,696,597 issued and outstanding shares, with fully diluted shares outstanding at 305,631,936 [15]

Core Insights - Arcutis Biotherapeutics, Inc. is set to present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026, with a fireside chat scheduled for April 14, 2026, at 11:00 am ET [1] Company Overview - Arcutis is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a portfolio of advanced targeted topicals approved for three major inflammatory skin diseases [2] - The company utilizes a unique dermatology development platform and expertise to create differentiated therapies targeting biologically validated areas, resulting in a robust pipeline for various inflammatory dermatological conditions [2]

Core Viewpoint - Gunnison Copper Corp. has filed an updated Preliminary Economic Assessment (PEA) for its Gunnison Copper Project, indicating strong economic viability and significant contributions to the U.S. copper supply [1][2]. Economic Assessment - The PEA outlines a large-scale copper project with an after-tax NPV8 of approximately US$2.0 billion, an internal rate of return of 22.5%, and a payback period of 3.9 years at a base case copper price of $4.60/lb [2][4]. - Under a higher copper price scenario of $5.75/lb, the after-tax NPV8 increases to approximately US$3.2 billion, with an internal rate of return of 31.8% and a payback period of 2.6 years [4]. Project Metrics - The project has a construction period of 24 months and a life of mine of 21 years, with a total of 641 million tons of mineralized material expected to be mined [6][7]. - The average annual copper production is projected to be 174 million pounds for the first 15 years, contributing significantly to U.S. refined copper production [7]. Economic Impact - The project is expected to create over 112,744 job years and generate $558 million in state and local taxes, $1.43 billion in federal taxes, and $21.9 billion in total economic output [4][5]. Financial Metrics - Key financial metrics at a $4.60/lb copper price include an average annual free cash flow of $366 million over the first 15 years and an EBITDA of $486 million [5][6]. - The cash cost is estimated at $1.70 per pound of copper, with sustaining cash costs of $2.00 and all-in sustaining costs of $2.05 per pound, positioning the project in the lower half of the global cost curve for copper mining [7]. Mineral Resource Estimate - The Gunnison Deposit's mineral resources are classified into Measured, Indicated, and Inferred categories, with a total of 846.1 million short tons at an average grade of 0.33% copper [10][12]. - The project has a significant amount of inferred resources, which are considered too speculative to be categorized as mineral reserves [4][9].

Core Insights - The Capital Group US Multi-Sector Income ETF (CGMS) is an actively managed fund launched on October 25, 2022, focusing on multi-sector bonds with a current AUM of $4.5 billion and a 30-day SEC yield of 5.72% [2][3] Fund Overview - CGMS invests primarily in high-yield corporate debt (37.2%), investment-grade corporate debt (35.7%), and securitized debt, with about 88% of its assets in U.S. securities [5][3] - The fund has a moderate credit risk profile, with 51% of assets in investment-grade rated securities [7] - The effective duration of the portfolio is 4.4 years, indicating moderate interest rate risk, with a 1% change in interest rates expected to affect the ETF's price by approximately 4.4% [8] Performance Metrics - CGMS has outperformed the Vanguard Total Bond Market Index ETF (BND) by 3.3% annualized since inception, with a total return of 29.90% compared to BND's 17.04% [11] - The fund's volatility is lower than that of BND, with a Sharpe ratio of 0.62 compared to BND's -0.01 [11] - Monthly distributions have remained stable at around $0.13 per share from 2023 to March 2026, all classified as ordinary income [13] Competitive Analysis - CGMS has the lowest expense ratio among its peers at 0.39% and ranks second in 12-month yield at 6.13% [16][17] - Compared to competitors, CGMS ranks third for total return and fourth for volatility, indicating a balanced risk-return profile [17] - CARY, a competitor, shows a higher return and lower volatility, presenting a more compelling risk-adjusted performance despite a higher expense ratio [18] Investment Suitability - CGMS is positioned for investors seeking an active bond ETF with a yield around 6% and moderate credit and interest rate risks, having demonstrated strong performance since inception [18][19]

Group 1 - OpenAI is focusing on monetizing its large user base by introducing ads, targeting the 850 million users who pay little or nothing for its services [1][2] - As of January, OpenAI's ChatGPT had approximately 900 million users, with a significant majority being non-paying users [1] - The company aims to generate $100 million in annual revenue from its ad program, which has just begun [2] Group 2 - OpenAI is in the early stages of developing its advertising business, having recently hired a former Meta executive to lead sales efforts [3] - Initial pricing for advertisers is set at $60 per 1,000 impressions, but the company is currently achieving around $15 per 1,000 impressions as it establishes its ad operations [3] - ChatGPT Go, priced at $8 per month, is the lowest tier of OpenAI's paid services, and both free and this tier's users will see ads [4]